Sale!
BPC 157 and TB 500 for sale
BPC 157 5mg COA
TB500 5mg COA

BPC-157 Peptide and TB-500 Peptide

 Selling fast! Get yours today  Same day shipping available

Original price was: $129.99.Current price is: $119.99.

Available on backorder

SKU: 100-1 Category:

Description

High-Quality TB 500 and BPC 157 Combo Pack for Sale Online

TB-500 and BPC-157 In Research

Introducing our exclusive combo pack featuring two potent peptides: TB-500 peptide and BPC-157 peptide. These peptides are renowned for their remarkable regenerative properties being studied in research.

TB-500 Research

TB-500 is a synthetic peptide analog of thymosin Beta 4, a naturally occurring peptide in mammals. With its 43 amino acid structure and nearly 5 g/mol molecular weight, TB-500 has been extensively studied for its potential in promoting healing and regeneration.

TB-500 Peptide

CAS Number: 77591-33-4

Formula: C212H350N56O78S

Sequence: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH

Molecular Weight: 4963.49 g/mol

Class: Polypeptide

Storage: Keep refrigerated upon reconstitution.

  • Lyophilized sample in sterile glass vial.
  • Minimum 99% pure.
  • 5mg TB 500 per vial.
  • Diluent and laboratory supplies not included.

BPC-157 Research

BPC-157 is a synthetic peptide derivative of a protein found in human gastric juice, known as Body Protection Compound (BPC). Despite its compact size of 15 amino acids, BPC-157 possesses a wide range of healing properties currently under study, making it a valuable tool in related research.

BPC-157 Peptide

CAS Number: 137525-51-0

Formula: C62H98N16O22

Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Molar Mass: 1,419.5 g/mol

Half life: 4 hours

Class: Polypeptide

Storage: Keep refrigerated upon reconstitution.

  • Lyophilized sample in sterile glass vial.
  • Minimum 98% pure.
  • 5mg BPC-157 per vial.
  • Diluent and laboratory supplies not included.

FAQs On BPC-157 and TB-500 Peptide

TB500 is a synthetic peptide analog of thymosin Beta 4, while BPC 157 is a synthetic peptide derivative of a protein found in human gastric juice. They have distinct molecular structures and mechanisms of action.
Sports Technology Labs offers high-quality TB500 peptides that are third-party tested for purity. Our products come with transparent lab certificates, ensuring the highest standards of quality and safety.
At Sports Technology Labs, we provide the purest BPC 157 peptides, rigorously tested and certified by accredited American third-party labs. Our commitment to quality ensures reliable results for your research endeavors.
TB500 and BPC 157 are researched in various fields, including wound healing, tissue regeneration, musculoskeletal repair, neurological disorders, gastrointestinal health, and more.
Both TB500 and BPC 157 should be stored in a cool, dry place away from direct sunlight. After reconstitution, they should be refrigerated to maintain stability and potency, ensuring reliable results for your research studies.

Why Choose Sports Technology Labs?

At Sports Technology Labs, we prioritize quality, purity, and transparency in every product we offer. Our TB-500 and BPC-157 peptides are meticulously tested and certified by accredited American third-party labs to ensure maximum efficacy and safety.

Our Commitment to Excellence:

  • Highest Quality Products: Pure compounds with guaranteed potency and effectiveness.
  • Transparent Business Practices: No hidden information or discreet payment methods.
  • Fast Shipping: Free shipping on orders over $149, with express shipping options available.
  • Customer Satisfaction: 10% discount for email subscribers and additional savings for cryptocurrency payments.

Unlock the potential of regeneration and healing research with our TB-500 and BPC-157 combo pack. Experience the difference with Sports Technology Labs.

Disclaimer: Our products are for in vitro laboratory research purposes only by licensed professionals and are not approved by the FDA for bodily introduction into humans or animals.

Scientific References:

1. Drmic D, Samara M, Vidovic T, Malekinusic D, Antunovic M, Vrdoljak B, Ruzman J, Milkovic Perisa M, Horvat Pavlov K, Jeyakumar J, Seiwerth S, Sikiric P. Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine. World J Gastroenterol. 2018 Dec 28;24(48):5462-5476. doi: 10.3748/wjg.v24.i48.5462. PMID: 30622376; PMCID: PMC6319139.

2. Huang T, Zhang K, Sun L, Xue X, Zhang C, Shu Z, Mu N, Gu J, Zhang W, Wang Y, Zhang Y, Zhang W. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015 Apr 30;9:2485-99. doi: 10.2147/DDDT.S82030. PMID: 25995620; PMCID: PMC4425239.

3. Amic F, Drmic D, Bilic Z, Krezic I, Zizek H, Peklic M, Klicek R, Pajtak A, Amic E, Vidovic T, Rakic M, Milkovic Perisa M, Horvat Pavlov K, Kokot A, Tvrdeic A, Boban Blagaic A, Zovak M, Seiwerth S, Sikiric P. Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine. World J Gastroenterol. 2018 Dec 21;24(47):5366-5378. doi: 10.3748/wjg.v24.i47.5366. PMID: 30598581; PMCID: PMC6305534.

4. Duzel A, Vlainic J, Antunovic M, Malekinusic D, Vrdoljak B, Samara M, Gojkovic S, Krezic I, Vidovic T, Bilic Z, Knezevic M, Sever M, Lojo N, Kokot A, Kolovrat M, Drmic D, Vukojevic J, Kralj T, Kasnik K, Siroglavic M, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights. World J Gastroenterol. 2017 Dec 28;23(48):8465-8488. doi: 10.3748/wjg.v23.i48.8465. PMID: 29358856; PMCID: PMC5752708.

5. Vukojević J, Siroglavić M, Kašnik K, Kralj T, Stanćić D, Kokot A, Kolarić D, Drmić D, Sever AZ, Barišić I, Šuran J, Bojić D, Patrlj MH, Sjekavica I, Pavlov KH, Vidović T, Vlainić J, Stupnišek M, Seiwerth S, Sikirić P. Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157. Vascul Pharmacol. 2018 Jul;106:54-66. doi: 10.1016/j.vph.2018.02.010. Epub 2018 Mar 3. PMID: 29510201.

6. Drmic D, Kolenc D, Ilic S, Bauk L, Sever M, Zenko Sever A, Luetic K, Suran J, Seiwerth S, Sikiric P. Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME. World J Gastroenterol. 2017 Aug 7;23(29):5304-5312. doi: 10.3748/wjg.v23.i29.5304. PMID: 28839430; PMCID: PMC5550779.

7. Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017 Mar;95(3):323-333. doi: 10.1007/s00109-016-1488-y. Epub 2016 Nov 15. PMID: 27847966.

8. Grabarevic Z, Tisljar M, Artukovic B, Bratulic M, Dzaja P, Seiwerth S, Sikiric P, Peric J, Geres D, Kos J. The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks. J Physiol Paris. 1997 May-Oct;91(3-5):139-49. doi: 10.1016/s0928-4257(97)89478-8. PMID: 9403788.

9. Škrlec K, Ručman R, Jarc E, Sikirić P, Švajger U, Petan T, Perišić Nanut M, Štrukelj B, Berlec A. Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities. Appl Microbiol Biotechnol. 2018 Dec;102(23):10103-10117. doi: 10.1007/s00253-018-9333-6. Epub 2018 Sep 6. PMID: 30191288.

10. Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, Klicek R, Radic B, Keller N, Sipos K, Jakir A, Udovicic M, Tonkic A, Kokic N, Turkovic B, Mise S, Anic T. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006 Dec;14(5-6):214-21. doi: 10.1007/s10787-006-1531-7. PMID: 17186181.

11. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Vrcic H, Sebecic B. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. doi: 10.2174/138161211796196954. PMID: 21548867.

12. Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, Mise S, Brcic I, Kolenc D, Klicek R, Banic T, Sever M, Kocijan A, Berkopic L, Radic B, Buljat G, Anic T, Zoricic I, Bojanic I, Seiwerth S, Sikiric P. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010 Mar;16(3):BR81-88. PMID: 20190676.

13. Unveiling the Wolverine Peptide: Exploring its Potential for Healing and Regeneration. Peptide Information (2023)

14.  Tokura Y, Nakayama Y, Fukada S, Nara N, Yamamoto H, Matsuda R, Hara T. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. J Biochem. 2011 Jan;149(1):43-8. doi: 10.1093/jb/mvq115. Epub 2010 Sep 29. PMID: 20880960.

15. Vasilopoulou E, Kolatsi-Joannou M, Lindenmeyer MT, White KE, Robson MG, Cohen CD, Sebire NJ, Riley PR, Winyard PJ, Long DA. Loss of endogenous thymosin β4 accelerates glomerular disease. Kidney Int. 2016 Nov;90(5):1056-1070. doi: 10.1016/j.kint.2016.06.032. Epub 2016 Aug 26. PMID: 27575556; PMCID: PMC5073078.

16. Brady RD, Grills BL, Schuijers JA, Ward AR, Tonkin BA, Walsh NC, McDonald SJ. Thymosin β4 administration enhances fracture healing in mice. J Orthop Res. 2014 Oct;32(10):1277-82. doi: 10.1002/jor.22686. Epub 2014 Jul 8. PMID: 25042765. 

17. Cheng P, Kuang F, Zhang H, Ju G, Wang J. Beneficial effects of thymosin β4 on spinal cord injury in the rat. Neuropharmacology. 2014 Oct;85:408-16. doi: 10.1016/j.neuropharm.2014.06.004. Epub 2014 Jun 14. PMID: 24937047.

18. Xiong Y, Mahmood A, Meng Y, Zhang Y, Zhang ZG, Morris DC, Chopp M. Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury. Ann N Y Acad Sci. 2012 Oct;1270:51-8. doi: 10.1111/j.1749-6632.2012.06683.x. PMID: 23050817; PMCID: PMC3547647.

19. Kleinman HK, Sosne G. Thymosin β4 Promotes Dermal Healing. Vitam Horm. 2016;102:251-75. doi: 10.1016/bs.vh.2016.04.005. Epub 2016 May 24. PMID: 27450738.

20. https://clinicaltrials.gov/show/NCT00598871

21. Exploring the Potential of Thymosin Peptide in Immune Function and Healing. Peptide Information (2023).

22. Goldstein AL, Kleinman HK. Advances in the basic and clinical applications of thymosin β4. Expert Opin Biol Ther. 2015;15 Suppl 1:S139-45. doi: 10.1517/14712598.2015.1011617. Epub 2015 Jun 22. PMID: 26096726.

You may also like…

Related products